share_log

4: Statement of changes in beneficial ownership of securities-Director Lewis-Hall Freda C

4: Statement of changes in beneficial ownership of securities-Director Lewis-Hall Freda C

4:持股變動聲明-董事 Lewis-Hall Freda C
美股SEC公告 ·  12/21 06:10

牛牛AI助理已提取核心訊息

Freda C Lewis-Hall, associated with Conduit Pharmaceuticals, has reported an upcoming transaction scheduled for December 18, 2024. The nature and details of this transaction have not been disclosed in the current filing.The reporting person's address is listed as 4851 Tamiami Trail North, Suite 200, Naples, FL, 34103. While the filing indicates a future event, it does not specify the type of securities involved or the quantity to be transacted. The relationship between Lewis-Hall and the issuer has not been explicitly stated in this announcement.
Freda C Lewis-Hall, associated with Conduit Pharmaceuticals, has reported an upcoming transaction scheduled for December 18, 2024. The nature and details of this transaction have not been disclosed in the current filing.The reporting person's address is listed as 4851 Tamiami Trail North, Suite 200, Naples, FL, 34103. While the filing indicates a future event, it does not specify the type of securities involved or the quantity to be transacted. The relationship between Lewis-Hall and the issuer has not been explicitly stated in this announcement.
Freda C Lewis-Hall與Conduit Pharmaceuticals有關,已報告一項計劃於2024年12月18日進行的交易。該交易的性質和細節在當前的申報中尚未披露。報告人的地址列爲4851 Tamiami Trail North, Suite 200, Naples, FL, 34103。雖然申報中指明瞭一個未來事件,但並沒有具體說明所涉及的證券類型或交易數量。Lewis-Hall與發行人之間的關係在此公告中沒有明確說明。
Freda C Lewis-Hall與Conduit Pharmaceuticals有關,已報告一項計劃於2024年12月18日進行的交易。該交易的性質和細節在當前的申報中尚未披露。報告人的地址列爲4851 Tamiami Trail North, Suite 200, Naples, FL, 34103。雖然申報中指明瞭一個未來事件,但並沒有具體說明所涉及的證券類型或交易數量。Lewis-Hall與發行人之間的關係在此公告中沒有明確說明。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。